Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 7, 2003, Pages 1575-1579

  Juhan Vague, I ^a   Alessi, M C ^a   Mavri, A ^a,b   Morange, P E ^a  

^a TIMONE HOSPITAL   (France)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Inflammation; Insulin resistance syndrome; Obesity; PAI 1; Vascular risk

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL; HEART DISEASE; HUMAN; INSULIN RESISTANCE; METABOLISM; OBESITY; PHYSIOLOGY; REVIEW; RISK;

ANIMALS; HEART DISEASES; HUMANS; INSULIN RESISTANCE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK;

EID: 0141832847     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00279.x     Document Type: Review

References (89)

1. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-2.
2. Reaven G, Syndrome X. 10 years after. Drugs 1999; 58 (Suppl. 1):19-20.
3. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
4. Kohler HP, Grant PJ. Plasminogen-activator inhibitor Type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the third national health and nutrition examination survey. JAMA 2002; 287: 356-9.
6. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
7. Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologia 2002; 45: 1201-10.
8. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and Type 2 diabetes mellitus. Ann NY Acad Sci 2002; 967: 363-78.
9. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001; 50 (Suppl. 1): 118-21.
10. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002; 5: 551-9.
11. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS). Circulation 2000; 102: 42-7.
12. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999; 19: 972-8.
13. Mohamed-Ali V, Goodrick S, Rawesh A, Miles JM, Katz D, Yudkin JS, Coppack SW. Human subcutaneous adipose tissue secretes interleukin-6 but not tumour necrosis factor-a in vivo. J Clin Endocrinol Metab 1997; 82: 4196-00.
14. Hotamisligil GS, Shargill NS, Spiegelman BMI. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
15. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
16. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of Type 2 diabetes mellitus, insulin resistance, inflammation and atherosclerosis. Am J Cardiol 2002; 90 (Suppl.): 27G-33G.
17. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
18. Stern MP. Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes 1995; 44: 369-74.
19. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-9.
20. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-8.
21. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 1996; 271: 665-8.
22. Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakis M, Kollias G, Moller DE. Targeted disruption of the tumor necrosis factoralpha gene: metabolic consequences in obese and nonobese mice. Diabetes 1997; 46: 1526-31.
23. Xu H, Hirosumi J, Uysal KT, Guler AD, Hotamisligil GS. Exclusive action of transmembrane TNFalpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology 2002; 143: 1502-11.
24. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factorkappaB activation by TNF-alpha is obligatory. Diabetes 2002; 51: 1319-36.
25. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of Type 2 diabetes. Diabetes 2002; 51: 455-61.
26. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6 and risk of developing Type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
27. Festa A, D'Agostino R, Tracy RP, Haffner SM. Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of Type 2 diabetes. The Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-7.
28. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 2001; 293: 1673-7.
29. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-46.
30. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72.
31. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost 1989; 61: 370-3.
32. Vague Ph, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, PA-inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-3.
33. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor Type 1 is related to insulin resistance. Metabolism 1993; 42: 945-9.
34. Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler Thromb Vasc Biol 1998; 18: 84-91.
35. Gray RP, Panahloo A, Mohamed-Ali V, Patterson DL, Yudkin JS. Proinsulin-like molecules and plasminogen activator inhibitor Type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis 1997; 130: 171-8.
36. Nordt T, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-70.
37. Haffner S, Mykkänen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in non diabetic subjects. Diabetes 1993; 42: 1297-302.
38. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-3.
39. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368-74.
40. Festa A, D'Agostino R, Mykkänen L, Tracy R, Howard BV, Haffner SM. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol 1999; 19: 605-10.
41. Meigs JB, Mittleman MA, Nathan D, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB,Wilson PW. Hyperinsulinemia hyperglycemia and impaired hemostasis. The Framingham Offspring Study. JAMA 2000; 283: 221-8.
42. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998; 22: 312-7.
43. Estellés A, Dalmau J, Falco C, Berbel O, Castello R, Espana F, Asnar J. Plasma PAI-1 levels in obese children - Effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost 2001; 86: 647-52.
44. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993; 16: 621-9.
45. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with Type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-9.
46. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491-4.
47. Morange PE, Aubert J, Peiretti F, Vague P, Lijnen HR, Verdier M, Negrel R, Juhan-Vague I, Alessi MC. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999; 48: 890-5.
48. Vulin AI, Stanley FM. A forkhead/winged helix-related transcription factor mediates insulin-incresed plasminogen activator inhibitor-1 gene transcription. J Biol Chem 2002; 277: 20169-76.
49. Kietzmann T, Samoylenko A, Roth U, Jungermann K. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 2002; 101: 907-14.
50. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-73.
51. Nilsson L, Banfi C, Diczfalusy U, Tremoli E, Hamsten A, Eriksson P. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1679-85.
52. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-8.
53. Vaughan D. Angiotensin and vascular fibrinolytic balance. Am J Hypertens 2002; 15: 3S-8S.
54. Grant PJ, Stickland MH, Wiles PG, Davies JA, Wales JK, Prentice CRM. Hormonal control of haemostasis during hypoglycaemia in diabetes mellitus. Thromb Haemost 1987; 57: 341-4.
55. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene 1 (Eg2-1) expression in mononuclear cells and reduces plasma tissue factor and plasminogen activator inhibitor 1 concentrations. J Clin Endocrinol Metab 2002; 87: 1419-22.
56. Samad F, Uysal T,Wiesbrock S, Pandey M, Hotamisligil S, Loskutoff J. Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999; 96: 6902-7.
57. Gruber F, Hufnagl P, Hofer-Warbinek R, Schmid JA, Breuss JM, Huber-Beckmann R, Lucerna M, Papac N, Harant H, Lindley I, DeMartin R, Binder BR. Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNFa induced PAI-1 expression. Blood 2003; 101: 3042-8.
58. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
59. Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non obese and obese individuals. Diabetologia 1998; 41: 65-71.
60. Cigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, Zeminian S, Cardinale C, Camin M, Chiaramonte E, De Sandre G, Lunardi C. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? Atherosclerosis 1999; 143: 81-90.
61. Gottschling-Zeller H, Birgel M, Rohrig K, Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism 2000; 49: 666-71.
62. Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, Fina F, Sentocnik JT, Stegnar M, Juhan-Vague I. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001; 44: 2025-31.
63. Bastelica D, Morange PE, Berthet B, Borghi H, Lacroix O, Grino M, Juhan-Vague I, Alessi MC. Stromal cells are the main PAI-1 producing cells in human fat. Evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002; 22: 173-8.
64. Alessi MC, Bastelica D, Morange PE, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I. Plasminogen activator inhibitor-1, transforming growth factor β 1 and body mass index are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-80.
65. Bastelica D, Mavri A, Verdier M, Bergoin M, Berthet B, Juhan-Vague I, Alessi MC. Relationships between fibrinolytic and inflammatory parameters in human adpose tissue: strong contribution of TNFα receptors to PAI-1 levels. Thromb Haemost 2002; 88: 481-7.
66. Samad F, Loskutoff DJ. The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thromb Haemost 1997; 78: 652-5.
67. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - role of the metabolic syndrome. Thromb Haemost 1996; 76: 69-73.
68. Bruckert E, Ankri A, Giral P, Turpin G. Relationship between plasma plasminogen activator inhibitor 1 and hepatic enzyme concentrations in hyperlipidemie patients. Thromb Haemost 1994; 72: 434-7.
69. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I. Plasma PAI-1 levels are more strongly related to liver steatosis thatn to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003; 69: in press.
70. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9.
71. Cesari M, Rossi GP. Plasminogen activator inhibitor Type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol 1999; 19: 1378-86.
72. Haffner SM, D'Agostino R, Mykkänen L, Hales CN, Savage PJ, Bergman RN, O'Leary D, Rewers M, Selby J, Tracy R, Saad MF. Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. Stroke 1998; 29: 1498-503.
73. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-63.
74. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infraction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
75. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor Type 1 in coronary artery atherectomy specimens from Type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998; 97: 2213-21.
76. Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Calafiore A, Pellegrini G, Vitacolonna E, Capani F, Consoli A. Plasminogen activator inhibitor Type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001; 21: 1378-82.
77. Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Agedependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002; 106: 491-6.
78. Konstantinides S, Schäfer K, Loskutoff DJ. Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain. Arterioscler Thromb Vasc Biol 2002; 22: 1943-5.
79. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoproten E-deficient mice. Arterioscler Thromb Vasc Biol 2002; 22: 499-5.
80. De Young MB, Tom C, Dichek DA. Plasminogen activator inhibitor Type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation 2001; 104: 1972-7.
81. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol 2002; 22: 934-9.
82. de Waard V, Arkenbout K, Carmeliet P, Lindner P, Pannekoek H. Plasminogen activator inhibitor-1 and vitronectin protect against stenosis in a murine carotid ligation model. Arterioscler Thromb Vasc Biol 2002; 22: 1978-83.
83. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000; 20: 1150-4.
84. Lijnen HR, Maquoi E, Morange P, Voros G, Van Hoef B, Kopp F, Collen D, Juhan-Vague I, Alessi MC. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 78-84.
85. Hoover-Plow J, Ellis J, Yuen L. In vivo plasminogen deficiency reduces fat accumulation. Thromb Haemost 2002; 87: 1011-9.
86. Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001; 15: 1840-2.
87. Vaughan DE, Rouleau J-L, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997; 96: 442-7.
88. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
89. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck J-E. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.